Rubicon Research Q1 FY27 Results (NSE: RUBICON)
Signal: Growth reaccelerated
The read
Q1FY27 marks a stronger operating inflection: consolidated revenue growth accelerated to +51.6% YoY from +43.6% in Q4FY26 and EBITDA margin reached 25.2% versus the prior-quarter 23% level, extending the company's four-quarter margin-expansion arc; however, EPS growth of +82.6% lagged PAT growth of +95.8% as the post-IPO share base expanded.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹534.34 Cr | +51.6% | +4.0% |
| EBIT | ₹119.66 Cr | N/A | |
| Net profit | ₹84.78 Cr | +95.8% | |
| EPS | ₹5.13 | +82.6% | |
| EBIT margin | 25.2% |
P&L walk
Revenue increased to ₹5,343.38 million, +51.6% YoY and +4.0% QoQ, while EBITDA margin was 25.2%; PAT rose to ₹847.81 million, +95.8% YoY, helped by operating growth, lower finance costs and a substantially lower deferred-tax charge.
Segments
The group reports one pharmaceutical-products segment; standalone PAT of ₹824.49 million represented 97.2% of consolidated PAT of ₹847.81 million, so current earnings remain concentrated in the parent despite the Arinna acquisition.
Key positives
- Consolidated revenue reached ₹5,343.38 million, +51.6% YoY, accelerating from +43.6% YoY in Q4FY26.
- EBITDA margin was 25.2%, up from the prior-results-series level of 23% in Q4FY26 and extending four consecutive quarters of margin expansion.
- Finance costs declined 12.5% YoY to ₹92.88 million while consolidated PAT rose 95.8% YoY to ₹847.81 million.
- R&D expenditure remained substantial at ₹600.69 million, equal to 11.2% of consolidated revenue, supporting the product-development-led model.
- The company completed the acquisition of 85% of Arinna Lifesciences for ₹1,759.17 million, broadening the inorganic growth platform.
Key concerns
- Consolidated gross margin compressed approximately 242bps YoY to 68.4% despite revenue growth of 51.6%, indicating cost absorption or mix pressure that the filing does not explain.
- EPS growth of 82.6% lagged PAT growth of 95.8% as paid-up equity capital increased to ₹165.38 million from ₹154.13 million.
- Depreciation increased 58.1% YoY to ₹151.39 million, faster than revenue growth, while the filing provides no asset-base disclosure to assess capex productivity.
- Consolidated revenue growth was only 4.0% QoQ, below the 9.7% standalone sequential growth, suggesting the acquired or overseas operations were not yet contributing proportionately to sequential momentum.
Research and educational content only. Not investment advice.